Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5682MR)

This product GTTS-WQ5682MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005340.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10457
UniProt ID Q14956
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5682MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11361MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ989MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ8280MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ6924MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ7514MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ13635MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ8887MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ11658MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW